Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Change in Account Payables (2016 - 2025)

Adma Biologics' Change in Account Payables history spans 13 years, with the latest figure at -$2.2 million for Q4 2025.

  • For Q4 2025, Change in Account Payables fell 155.89% year-over-year to -$2.2 million; the TTM value through Dec 2025 reached $2.3 million, down 43.86%, while the annual FY2025 figure was $2.3 million, 43.86% down from the prior year.
  • Change in Account Payables reached -$2.2 million in Q4 2025 per ADMA's latest filing, up from -$4.9 million in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $13.8 million in Q3 2022 to a low of -$12.0 million in Q4 2022.
  • Average Change in Account Payables over 5 years is $623750.0, with a median of $66000.0 recorded in 2023.
  • Peak YoY movement for Change in Account Payables: soared 16280.0% in 2024, then plummeted 401.36% in 2025.
  • A 5-year view of Change in Account Payables shows it stood at -$4.9 million in 2021, then plummeted by 146.61% to -$12.0 million in 2022, then skyrocketed by 141.73% to $5.0 million in 2023, then decreased by 21.07% to $3.9 million in 2024, then tumbled by 155.89% to -$2.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Change in Account Payables are -$2.2 million (Q4 2025), -$4.9 million (Q3 2025), and $9.3 million (Q2 2025).